New $5 HPV test could save lives in poor countries
NCT ID NCT05431699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking if a new, low-cost HPV test called ScreenFire works as well as the standard test for finding cervical cancer risk. About 9,100 women aged 30-59 will use a self-collection method. The goal is to see if the test is accurate, reduces follow-up visits, and is cost-effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ScreenFire HPV test (diagnostic test)
- What this could lead to
- If successful, this could provide a cheaper, easier way to screen for cervical cancer, especially in low-resource settings.
- What could go wrong
- This is a validation study, not a treatment trial. The new test may not be as accurate as the standard one, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ministerio de Salud
San Salvador, El Salvador
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the HPV vaccine fully protect transgender women and people with HIV?
- Tweets that tell a story: a new approach to boosting HPV vaccination
- Could HPV shots start earlier? study tests vaccine in kids as young as 4
- Immune cell therapy takes on HPV
- ERs may soon offer At-Home HPV tests to reach women who skip screenings
- Could a common numbing drug help fight throat cancer?